Patents Assigned to NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT
-
Publication number: 20160184250Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: ApplicationFiled: March 9, 2016Publication date: June 30, 2016Applicants: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Ko RII, Kiwamu TAKAHASHI, Naomi HAGA, Fuminori ABE, Tohru TANAKA, Motowo NAKAJIMA, Hidenori ITO
-
Patent number: 9314443Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: September 12, 2012Date of Patent: April 19, 2016Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Publication number: 20150174090Abstract: An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: ApplicationFiled: July 3, 2013Publication date: June 25, 2015Applicants: SBI PHARMACEUTICALS CO., LTD., National Center for Child Health and DevelopmentInventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Naomi Haga, Kiwamu Takahashi, Hidenori Ito, Ko Rii
-
Publication number: 20100216245Abstract: The present invention provides a frozen cell immobilized product which is obtained by applying a technique for freezing cultured cells to a technique for forming primary hepatocyte spheroids through co-culturing, and which can improve performance in an examination or a test using the technique for forming primary hepatocyte spheroids; a primary hepatocyte culture tool; and a method for producing the primary hepatocyte culture tool. According to the invention, a cell-adhesion region of a culture substrate is defined in a pattern; animal-derived adherent cells are cultured on the cell-adhesion region; and the cultured cells are frozen together with a freezing culture medium.Type: ApplicationFiled: September 11, 2008Publication date: August 26, 2010Applicants: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT, TOYO GOSEI CO., LTD.Inventors: Shin Enosawa, Yoshitaka Miyamoto, Takeshi Ikeya
-
Patent number: 7172867Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.Type: GrantFiled: July 1, 2003Date of Patent: February 6, 2007Assignees: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & DevelopmentInventors: Ryoichi Hashida, Shinji Kagaya, Yuji Sugita, Hirohisa Saito
-
Patent number: 7148011Abstract: The differential display method was used to search for a gene whose expression level in eosinophils collected from patients with atopic dermatitis differs in the exacerbation stage and in the remission stage. As a result, gene “2090-05” showing a significant increase in expression in eosinophils of patients in the remission stage was isolated. This gene is usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.Type: GrantFiled: September 21, 2001Date of Patent: December 12, 2006Assignees: Japan as represented by General Director of Agency of National Center for Child Health and Development, Eisai Co., Ltd., Genox Research, Inc.Inventors: Yuji Sugita, Ryoichi Hashida, Kaoru Ogawa, Tomoko Fujishima, Takeshi Nagasu, Gozoh Tsujimoto, Eiki Takahashi
-
Patent number: 7115373Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.Type: GrantFiled: June 27, 2003Date of Patent: October 3, 2006Assignees: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center For Child Health & DevelopmentInventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
-
Publication number: 20040214192Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.Type: ApplicationFiled: June 27, 2003Publication date: October 28, 2004Applicants: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & DevelopmentInventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
-
Publication number: 20040214231Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.Type: ApplicationFiled: July 1, 2003Publication date: October 28, 2004Applicants: Genox Research, Inc., Japan as Rep. by General Director of Agency of National Center for Child Health and DevelopmentInventors: Ryoichi Hashida, Shinji Kagaya, Yuji Sugita, Hirohisa Saito
-
Publication number: 20030224423Abstract: B1799 gene, whose expression level increases significantly in the patient group, was successfully identified by screening for a gene which shows difference in expression in blood collected from multiple healthy subjects and patients of allergic diseases employing the differential display method. The gene expression level is specifically high in T cells and increased due to T cell activation. This gene can be used in testing for allergic diseases and also in screening for therapeutic agents for allergic diseases.Type: ApplicationFiled: April 3, 2003Publication date: December 4, 2003Applicants: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & DevelopmentInventors: Yoshiko Matsumoto, Yukiho Imai, Nei Yoshida, Tadahiro Oshida, Yuji Sugita, Hirohisa Saito
-
Publication number: 20030219796Abstract: The SOCS3 gene has been identified as a gene whose expression level in T cells of patients with an atopic disorder is significantly higher than that of the normal healthy subjects. The present inventors found that this gene can be used in testing for allergic diseases and in screening for therapeutic agents. The present invention enables screening for compounds useful in the treatment of allergic diseases.Type: ApplicationFiled: February 27, 2003Publication date: November 27, 2003Applicants: Genox Research, Inc., Japan as represented by general director of agency of National Center for Child Health & DevelopmentInventors: Naoko Nagata, Tadahiro Oshida, Yuji Sugita, Masato Kubo, Hirohisa Saito
-
Publication number: 20030148312Abstract: An objective of the present invention is to provide a method for testing for an allergic disease and a method of screening for a therapeutic agent for allergic diseases.Type: ApplicationFiled: July 24, 2002Publication date: August 7, 2003Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENTInventors: Nei Yoshida, Naoko Nagata, Tadahiro Oshida, Ryoichi Hashida, Yuji Sugita, Hirohisa Saito